Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JANX 009

Next Previous
X
Search
Drug Profile

JANX 009

Alternative Names: Costim bispecific - Janux Therapeutics; Costim-bispecific; Costimulatory bispecific - Janux Therapeutics; costimulatory bispecific TRACIr; JANX-009; PD-L1xCD28 TRACIr; PD-L1xCD28 TRACIr - Janux Therapeutics

Latest Information Update: 04 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janux Therapeutics
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Peptides; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 15 Feb 2023 Janux Therapeutics has patents pending for JANX 009 in USA
  • 15 Feb 2023 Janux Therapeutics has PCT pending for JANX 009 in undisclosed countries
  • 16 May 2022 to be QCed; KDM updated and FE updated

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top